PFTK1在人非小细胞肺癌中的表达及临床意义

doi:10.3969/j.issn.1004-616x.2016.03.015

癌变·畸变·突变 ›› 2016, Vol. 28 ›› Issue (3): 231-235.doi: 10.3969/j.issn.1004-616x.2016.03.015

PFTK1在人非小细胞肺癌中的表达及临床意义

翟晓然, 江妹, 赵晓婷, 顾勐, 岳文涛

首都医科大学附属北京胸科医院, 北京市结核病胸部肿瘤研究所, 细胞生物学实验室, 北京 101100

收稿日期:2015-12-28 修回日期:2016-03-01 出版日期:2016-05-31 发布日期:2016-05-31
通讯作者: 岳文涛,E-mail:wentaoyue@hotmail.com E-mail:wentaoyue@hotmail.com
作者简介:翟晓然,E-mail:xiaoranzqwm@163.com。
基金资助:
国家自然科学基金(61431019);首都卫生发展科研专项(首发2014-2-1041);北京市优秀人才培养资助(2013D003034000028)

Clinical significance of PFTK1 expression in human non-small cell lung cancer

ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao

Department of Cellular & Molecular Biology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101100, China

Received:2015-12-28 Revised:2016-03-01 Online:2016-05-31 Published:2016-05-31

摘要/Abstract

摘要： 目的:研究PFTAIRE蛋白激酶1(PFTK1)在人类非小细胞肺癌(NSCLC)组织中的表达及其与NSCLC临床病理特征之间的关系,揭示PFTK1的表达在NSCLC中的临床意义。方法:采用免疫组织化学方法检测119例NSCLC组织中PFTK1的表达情况,并用χ²检验比较样本率,Kaplan-Meier法计算生存率,Log-Rank检验进行生存率的比较。结果:PFTK1在NSCLC组织中呈胞核和胞浆阳性。与癌旁组织比较,在119例NSCLC组织中,有76例肺癌组织PFTK1表达水平升高,占63.9%(76/119)。PFTK1的表达在NSCLC不同T分期间以及是否存在淋巴结转移组间的差异均具有统计学意义(P均<0.05),与年龄、性别、临床分期、病理分级、病理类型、肿瘤大小以及区域淋巴结N分期无明显相关性(P>0.05)。在肺鳞癌患者中控制分层因素N分期后进行生存分析显示PFTK1的表达水平越高,患者生存时间越短(P<0.05)。结论:PFTK1在人NSCLC中表达水平升高,并且PFTK1的表达与NSCLC的T分期及淋巴结转移具有相关性,影响NSCLC患者预后。PFTK1有望成为NSCLC潜在的生物学标志。

关键词: PFTAIRE蛋白激酶1, 非小细胞肺癌, 免疫组织化学染色, 生存时间

Abstract: OBJECTIVE:To investigate the expression of PFTAIRE protein kinase 1(PFTK1) in human non-small cell lung cancer (NSCLC) and to analyze its clinical significance. METHODS:Immunohistochemistry was used to detect the protein expression of PFTK1 in 119 cases of NSCLC. The sample rate was tested by chi-square test. Kaplan-Metier method was used to calculate survival rates and survival rates were tested by Log-Rank test. RESULTS:In NSCLC tissues, PFTK1 existed mainly in the cytoplasm and nucleus. In the 119 cases, PFTK1 expression was higher in cancer than in adjacent normal alveolar epithelium tissues, and the ratio was 63.9% (76/119). PFTK1 expression was significantly correlated with both different T (primary tumor) stage and lymph node metastasis (P<0.05), whereas it was not correlated with age, sex, clinical stage, pathological grade, pathology type, tumor size and N (regional lymph node)stage (P>0.05). In patients with lung squamous cell carcinoma, if stratification factor N stage was controlled, the survival analysis showed that when the expression level of PFTK1 was higher the overall survival time of patients was shorter(P<0.05). CONCLUSION:PFTK1 was overexpressed in NSCLC, was closely associated with T stage and lymph node metastasis, and affected prognosis of patients. PFTK1 may become a potential biomarker for NSCLC.

Key words: PFTAIRE protein kinase 1, non-small cell lung cancer, immunohistochemistry, survival time

中图分类号:

R734.2

翟晓然, 江妹, 赵晓婷, 顾勐, 岳文涛. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3): 231-235.

ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.

参考文献

[1] Putora PM,Ess S,Panje C,et al. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)[J]. Clin Exp Metastasis,2015,32(2):143-149.
[2] Robinson AG,Young K,Balchin K,et al. Causes of death and subsequent treatment after initial radical or palliative therapy of stage III non-small-cell lung cancer[J]. Curr Oncol,2015,22(5):333-340.
[3] Zhang W,Pal SK,Liu X,et al. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer[J]. PLoS One,2013,8(5):e65121.
[4] Neri S,Ishii G,Taira T,et al. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma[J]. Ann Surg Oncol,2012,19(12):3953-3962.
[5] Yang L,Zhu J,Huang H,et al. PFTK1 promotes gastric cancer progression by regulating proliferation,migration and invasion[J]. PLoS One,2015,10(10):e140451.
[6] Fan S,Zhao C,Zhang L,et al. Knockdown of PFTK1 inhibits the migration of glioma cells[J]. J Mol Neurosci,2015,57(2):257-264.
[7] Gu X,Wang Y,Wang H,et al. Upregulated PFTK1 promotes tumor cell proliferation,migration,and invasion in breast cancer[J]. Med Oncol,2015,32(7):195.
[8] Pang EY,Bai AH,To KF,et al. Identification of PFTAIRE protein kinase 1,a novel cell division cycle-2 related gene,in the motile phenotype of hepatocellular carcinoma cells[J]. Hepatology,2007,46(2):436-445.
[9] Miyagaki H,Yamasaki M,Miyata H,et al. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer,2012,106(5):947-954.
[10] I H,Cho JY. Lung cancer biomarkers[J]. Adv Clin Chem,2015,72:107-170.
[11] Leung WK,Ching AK,Chan AW,et al. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility[J]. Oncogene,2011,30(44):4464-4475.
[12] Lazzaro MA,Albert PR,Julien JP. A novel cdc2-related protein kinase expressed in the nervous system[J]. J Neurochem,1997,69(1):348-364.
[13] Yang T,Chen JY. Identification and cellular localization of human PFTAIRE1[J]. Gene,2001,267(2):165-172.
[14] Gao Y,Jiang M,Yang T,et al. A cdc2-related protein kinase hPFTAIRE1 from human brain interacting with 14-3-3 proteins[J]. Cell Res,2006,16(6):539-547.
[15] Pollack D,Xiao Y,Shrivasatava V,et al. CDK14 expression is down-regulated by cigarette smoke in vivo and in vitro[J]. Toxicol Lett,2015,234(2):120-130.
[16] Malumbres M,Harlow E,Hunt T,et al. Cyclin-dependent kinases:a family portrait[J]. Nat Cell Biol,2009,11(11):1275-1276.
[17] Yang HJ,Wang L,Wang M,et al. Serine/threonine-protein kinase PFTK1 modulates oligodendrocyte differentiation via PI3K/AKT pathway[J]. J Mol Neurosci,2015,55(4):977-984.
[18] Shu F,Lv S,Qin Y,et al. Functional characterization of human PFTK1 as a cyclin-dependent kinase[J]. Proc Natl Acad Sci USA,2007,104(22):9248-9253.
[19] Suryadinata R,Sadowski M,Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates[J]. Biosci Rep,2010,30(4):243-255.
[20] Sun T,Co NN,Wong N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma[J]. Biochem Biophys Res Commun,2014,449(1):163-168.
[21] Li S,Jiang M,Wang W,et al. 14-3-3 binding to cyclin Y contributes to cyclin Y/CDK14 association[J]. Acta Biochim Biophys Sin (Shanghai),2014,46(4):299-304.

PFTK1在人非小细胞肺癌中的表达及临床意义

Clinical significance of PFTK1 expression in human non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[3]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[4]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[5]	应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.
[6]	朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.
[7]	吴健彬, 江妹, 王玥, 许晶, 岳文涛, 王子彤. 非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较[J]. 癌变·畸变·突变, 2018, 30(2): 114-119.
[8]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[9]	张静, 滕宇, 赵晓婷, 江妹, 岳文涛. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017, 29(4): 245-250.
[10]	宋杰, 李萍, 于雪新, 冯林, 高燕宁, 肖汀. Syntenin在非小细胞肺癌中的表达及其与患者总生存期的关系[J]. 癌变·畸变·突变, 2017, 29(2): 102-105.
[11]	李超, 倪娟, 徐伟江, 汪旭. miR-22、miR-34a与叶酸介导的一碳代谢在非小细胞肺癌和肝细胞癌中的调控作用[J]. 癌变·畸变·突变, 2016, 28(4): 317-320.
[12]	吴娟, 杜芸, 王珩, 吴家宁, 赵银环, 王蕊, 张艳, 纪晓坤. 非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义[J]. 癌变·畸变·突变, 2016, 28(1): 27-31.
[13]	凌兵,冯林,程书钧. DENND2D通过调控PARP1对非小细胞肺癌细胞系H1299中顺铂细胞毒性的影响[J]. 癌变·畸变·突变, 2013, 25(2): 87-90.
[14]	孙国贵,张钧,胡万宁. Survivin和Cox-2蛋白与非小细胞肺癌危险因素的系统评价[J]. , 2012, 24(3): 199-204.
[15]	王凤云，张艳桥*，罗明，武云，李鹏，李志伟，孙伟. p-Stat3、VEGF-C和MMP-2在非小细胞肺癌中的表达及其与淋巴结转移的关系[J]. , 2011, 23(2): 107-110.